NASDAQ:WVE Wave Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Wave Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.56 -0.46 (-4.59 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$8.87Now: $9.56▼$9.9250-Day Range$8.78MA: $12.20▼$19.5452-Week Range$6.61Now: $9.56▼$39.98Volume4.18 million shsAverage Volume733,051 shsMarket Capitalization$348.50 millionP/E RatioN/ADividend YieldN/ABeta0.19 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, Wave Life Sciences has a forecasted upside of 114.4% from its current price of $9.56.Amount of Analyst CoverageWave Life Sciences has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesWave Life Sciences has received 322 “outperform” votes. (Add your “outperform” vote.)Underperform VotesWave Life Sciences has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentWave Life Sciences has received 53.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote “Outperform” if you believe WVE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,020,043.00 in company stock.Percentage Held by Insiders38.20% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.67% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to grow in the coming year, from ($3.92) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:WVE Previous Symbol CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone65-6236-3388Debt Debt-to-Equity Ratio1.36 Current Ratio1.33 Quick Ratio1.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.98 million Price / Sales21.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book5.14Profitability EPS (Most Recent Fiscal Year)($5.72) Net Income$-193,640,000.00 Net Margins-1,562.01% Return on Equity-401.32% Return on Assets-72.82%Miscellaneous Employees250 Outstanding Shares36,454,000Market Cap$348.50 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $9.56 -0.46 (-4.59 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive WVE News and Ratings via Email Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter. Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions How has Wave Life Sciences' stock been impacted by COVID-19 (Coronavirus)? Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, WVE shares have increased by 17.7% and is now trading at $9.56. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Wave Life Sciences? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Wave Life Sciences. When is Wave Life Sciences' next earnings date? Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Wave Life Sciences. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd (NASDAQ:WVE) posted its earnings results on Monday, August, 10th. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.03) by $0.12. The business had revenue of $3.03 million for the quarter, compared to analysts' expectations of $7.04 million. Wave Life Sciences had a negative return on equity of 401.32% and a negative net margin of 1,562.01%. View Wave Life Sciences' earnings history. What price target have analysts set for WVE? 6 brokers have issued 1 year target prices for Wave Life Sciences' stock. Their forecasts range from $10.00 to $27.00. On average, they expect Wave Life Sciences' share price to reach $20.50 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View analysts' price targets for Wave Life Sciences. Who are some of Wave Life Sciences' key competitors? Some companies that are related to Wave Life Sciences include Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Generation Bio (GBIO), Rocket Pharmaceuticals (RCKT), Mersana Therapeutics (MRSN), Epizyme (EPZM), Trillium Therapeutics (TRIL), Arcus Biosciences (RCUS), Amneal Pharmaceuticals (AMRX), INDIVIOR PLC/S (INVVY), Passage Bio (ZNTL), Akero Therapeutics (AKRO) and Tocagen (TOCA). View all competitors. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro BioTech (ADRO), ImmunoGen (IMGN) and Micron Technology (MU). Who are Wave Life Sciences' key executives? Wave Life Sciences' management team includes the following people: Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)Dr. Takeshi Wada, Scientific Advisor (Age 57)Mr. Keith C. Regnante, Chief Financial Officer (Age 49) What is Wave Life Sciences' stock symbol? Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE." Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (6.56%), Nantahala Capital Management LLC (4.79%), Jacobs Levy Equity Management Inc. (1.04%), Point72 Asset Management L.P. (0.78%), Charles Schwab Investment Management Inc. (0.32%) and Nuveen Asset Management LLC (0.29%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View institutional ownership trends for Wave Life Sciences. Which major investors are selling Wave Life Sciences stock? WVE stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, PDT Partners LLC, Matisse Capital, Bank of America Corp DE, WS Management Lllp, Amia Capital LLP, Charles Schwab Investment Management Inc., and Nuveen Asset Management LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, and Paul Bolno. View insider buying and selling activity for Wave Life Sciences. Which major investors are buying Wave Life Sciences stock? WVE stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Jacobs Levy Equity Management Inc., Point72 Asset Management L.P., Bessemer Group Inc., Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., Athanor Capital LP, and Virtus ETF Advisers LLC. View insider buying and selling activity for Wave Life Sciences. How do I buy shares of Wave Life Sciences? Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Wave Life Sciences' stock price today? One share of WVE stock can currently be purchased for approximately $9.56. How big of a company is Wave Life Sciences? Wave Life Sciences has a market capitalization of $348.50 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe. What is Wave Life Sciences' official website? The official website for Wave Life Sciences is www.wavelifesciences.com. How can I contact Wave Life Sciences? Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
